Nofiate 200

Indications

Nofiate is indicated for managing hyperlipidemias of types IIa, IIb, III, IV, and V in patients who have not achieved adequate control through diet and other measures.

Pharmacology

Fenofibrate, a fibric acid derivative, is rapidly converted in the body to its active form, fenofibric acid, after oral administration. This active form effectively lowers total cholesterol, LDL cholesterol, Apo-lipoprotein B, total triglycerides, and VLDL levels. Additionally, Fenofibrate increases HDL cholesterol and the apo-proteins apoAI and apoAII. It also lowers serum uric acid levels by promoting its urinary excretion. The micronized formulation of Nofiate enhances absorption compared to the non-micronized version.

Dosage & Administration

• For hypercholesterolemia or mixed hyperlipidemia in adults: Start with 200 mg per day.
• For hypertriglyceridemia in adults: Begin with a dose ranging from 67 to 200 mg per day.
• Dosing should be tailored to individual patient responses. It is recommended to take Fenofibrate with meals to optimize its bioavailability, or as prescribed by your healthcare provider.

Always follow your healthcare provider’s advice.

Interactions

Nofiate may enhance the anticoagulant effects of warfarin. When taken alongside antidiabetic medications, it may improve glucose tolerance. Caution is advised when combining Nofiate with cyclosporine due to increased nephrotoxicity risk. Although there is a potential for rhabdomyolysis when used with HMG-CoA reductase inhibitors, low-dose statins have generally been well tolerated with Nofiate.

Contraindications

Fenofibrate is contraindicated in individuals with hypersensitivity to the drug, severe renal or hepatic impairment, gallbladder disease, breastfeeding mothers, and those with photosensitivity to ketoprofen.

Side Effects

Common side effects include gastrointestinal issues (nausea, anorexia, gastric pain), pruritus, urticaria, impotence, as well as headache, dizziness, vertigo, fatigue, hair loss, and potential myotoxicity.

Pregnancy & Lactation

Fenofibrate is not recommended for use during pregnancy.

Precautions & Warnings

Use caution in patients with renal conditions, as increases in serum creatinine may indicate potential myotoxicity. Discontinue use if myotoxicity is suspected or if there is a significant rise in creatinine kinase levels. Liver function tests are advised every three months during the first year of treatment.

Overdose Effects

There is no specific antidote for Nofiate overdose. General supportive care should be provided, including monitoring vital signs and clinical status. Due to high plasma protein binding, hemodialysis is not recommended.

Therapeutic Class

Fibrates

Storage Conditions

Store below 30°C, away from light, and out of reach of children.